7Preskorn SH.Pharmacokinetics and therapeutics of acute intramucular ziprasidone[ J ].Clin Pharmacokinet,2005,44:1117.
8Stimmel GL,Gutierrez MA,Lee V.Ziprasidone:an atypical antipsychotic drug for the treatment of schizophrenia[ J].Clin Ther,2002,24:21-37.
9Elming H,Sonne J,Lublin HK.The importance of the QT interval:a review of the literature[ J ].Acta Psychiatr Scand,2003,107:96-101.
10Taylor DM.Antipsychotics and QT prolongation[ J ].Acta Psychiatr Scand,2003,107:85-95.
二级参考文献24
1Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry, 2002; 63 [Suppl, 9]: 12-17.
2Casey DE,Zorn SH. The pharmacology of weigh gain with antipsychotics. J Clin Psychiatry, 2001; 62 [Suppl, 7]:4-10.
3Emsley R, Oosthuizen P. The new and evolving pharmacotherapy of schizophrenia. Psychiat Clin North Am.2003; 26 (1): 141-163.
4Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry, 2003; 64 [Suppl,8]: 15-21.
5Stimmel GL, Guitierrez MA, Lee V. Ziprasidone : an atypical antipsychotic drug for the treatment of schizophrenia.Clinical Therapeutics, 2002; 24 (1): 21-37.
6Kaye NS. Ziprasidone augmentation of clozapine in patients. J Clin Psychiatry, 2003; 64 (2): 215-216.
7Ketter TA, Wang PW. The emerging differential role of GABAergic and antiglutamatergic agents in bipolar disorders. J Clin Psychiatry, 2003; 64 [Suppl, 3]: 15-20.
8Nolan BP, Schulte JJ. Mania associated with initiation of ziprasidone. J Clin Psychiatry, 2003; 64 (3): 336.
9McDougle CJ ,Stigler KA ,Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry; 2003; 64 [Suppl, 4]: 16-25.
10Weiden P J, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry, 2003;64 (5): 580-588.
